Aranesp Performance Strong Heading Into "Transition" Time, Amgen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is talking with oncologists about Aranesp ahead of a switch in Medicare reimbursement in January 2005. U.S. sales for the red blood cell product were up 32% in the third quarter.